Ethical Holdings Issues Pathfinder Listing
Ethical Holdings of the UK has published the pathfinder listingparticulars for its proposed flotation on the London Stock Exchange by means of an institutional placing (Marketletter May 19). The proceeds of the placing will be used to progress the development of its product candidates, and to fund the acquisition of the Irish pharmaceutical company Clonmel (Marketletter June 2).
The company has proven and patented oral and transdermal drug delivery technologies and a portfolio of 42 products, which are developed or under development. Ethical says that 18 products have received
regulatory approval in at least one country, and 11 of these are currently marketed. It has 24 products in development, which include ones aimed at large markets such as hormone replacement therapy, cardiovascular disease and pain management.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze